CD276 and neoplasm: Owing to the lack of significant difference in survival between anti-IgG and anti–B7-H3 mAbs, we analyzed tumor-infiltrating immune cells among (a) anti-IgG, (c) alisertib and anti-IgG, and (d) alisertib and anti–B7-H3 mAbs.